Pulmonx Zephyr® EBV gets into COPD “Bible”

« Back to Industry News

23/11/2016

For the first time, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has recommended use of endobronchial valves in bronchoscopic lung volume reduction for patients with advanced emphysema and absence of collateral ventilation.

Each year, GOLD issues a report entitled “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease,” which is used worldwide as a “strategy” document for healthcare professionals to implement effective management programs based on local healthcare systems. The report issues recommendations for the management of COPD based on the best scientific information available.

GOLD has issued a substantial revision to its management recommendations for chronic obstructive pulmonary disease (COPD) that now includes Pulmonx’s Zephr® Endobronchial Valve (EBV). The updated recommendations are based on new clinical evidence published in the past 15 months supporting Zephyr, including three randomized controlled trials (BeLieVeR-HIFi, STELVIO and IMPACT).

In describing the clinical evidence to support this recommendation, the GOLD report notes, “In select patients with advanced emphysema, bronchoscopic interventions reduce end-expiratory lung volume and improves exercise tolerance, health status and lung function 6-12 months following treatment.”

The Zephyr EBV remains an investigational device in the United States, limited by U.S. law to investigational use only.

 


Click here to view the full related article.

« Back to Industry News